vs
Antero Midstream Corp（AM）与Amphastar Pharmaceuticals, Inc.（AMPH）财务数据对比。点击上方公司名可切换其他公司
Antero Midstream Corp的季度营收约是Amphastar Pharmaceuticals, Inc.的1.6倍（$291.1M vs $183.1M），Antero Midstream Corp净利率更高（41.5% vs 13.3%，领先28.1%），Amphastar Pharmaceuticals, Inc.同比增速更快（-1.8% vs -7.3%），过去两年Antero Midstream Corp的营收复合增速更高（3.9% vs 3.2%）
Antero Midstream Corp是美国能源企业，注册地为特拉华州，总部设于科罗拉多州丹佛市。公司全部油气储量均位于阿巴拉契亚盆地，采用水力压裂技术开采，核心业务涵盖油气勘探开发相关领域。
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
AM vs AMPH — 直观对比
营收规模更大
AM
是对方的1.6倍
$183.1M
营收增速更快
AMPH
高出5.5%
-7.3%
净利率更高
AM
高出28.1%
13.3%
两年增速更快
AM
近两年复合增速
3.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $291.1M | $183.1M |
| 净利润 | $120.7M | $24.4M |
| 毛利率 | — | 46.8% |
| 营业利润率 | 60.9% | 19.4% |
| 净利率 | 41.5% | 13.3% |
| 营收同比 | -7.3% | -1.8% |
| 净利润同比 | 2.1% | -35.7% |
| 每股收益（稀释后） | $0.25 | $0.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMAMPH
| Q1 26 | $291.1M | — | ||
| Q4 25 | $297.0M | $183.1M | ||
| Q3 25 | $294.8M | $191.8M | ||
| Q2 25 | $305.5M | $174.4M | ||
| Q1 25 | $291.1M | $170.5M | ||
| Q4 24 | $287.5M | $186.5M | ||
| Q3 24 | $269.9M | $191.2M | ||
| Q2 24 | $269.8M | $182.4M |
净利润AMAMPH
| Q1 26 | $120.7M | — | ||
| Q4 25 | $51.9M | $24.4M | ||
| Q3 25 | $116.0M | $17.4M | ||
| Q2 25 | $124.5M | $31.0M | ||
| Q1 25 | $120.7M | $25.3M | ||
| Q4 24 | $111.2M | $38.0M | ||
| Q3 24 | $99.7M | $40.4M | ||
| Q2 24 | $86.0M | $37.9M |
毛利率AMAMPH
| Q1 26 | — | — | ||
| Q4 25 | — | 46.8% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 49.6% | ||
| Q1 25 | — | 50.0% | ||
| Q4 24 | — | 46.5% | ||
| Q3 24 | — | 53.3% | ||
| Q2 24 | — | 52.2% |
营业利润率AMAMPH
| Q1 26 | 60.9% | — | ||
| Q4 25 | 33.8% | 19.4% | ||
| Q3 25 | 61.2% | 13.2% | ||
| Q2 25 | 61.0% | 24.2% | ||
| Q1 25 | 60.9% | 21.9% | ||
| Q4 24 | 61.8% | 24.2% | ||
| Q3 24 | 60.2% | 29.8% | ||
| Q2 24 | 56.6% | 30.3% |
净利率AMAMPH
| Q1 26 | 41.5% | — | ||
| Q4 25 | 17.5% | 13.3% | ||
| Q3 25 | 39.3% | 9.0% | ||
| Q2 25 | 40.8% | 17.8% | ||
| Q1 25 | 41.5% | 14.8% | ||
| Q4 24 | 38.7% | 20.4% | ||
| Q3 24 | 37.0% | 21.1% | ||
| Q2 24 | 31.9% | 20.8% |
每股收益（稀释后）AMAMPH
| Q1 26 | $0.25 | — | ||
| Q4 25 | $0.11 | $0.51 | ||
| Q3 25 | $0.24 | $0.37 | ||
| Q2 25 | $0.26 | $0.64 | ||
| Q1 25 | $0.25 | $0.51 | ||
| Q4 24 | $0.23 | $0.74 | ||
| Q3 24 | $0.21 | $0.78 | ||
| Q2 24 | $0.18 | $0.73 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.4M | $282.8M |
| 总债务越低越好 | $3.2B | $608.7M |
| 股东权益账面价值 | $2.0B | $788.8M |
| 总资产 | $5.9B | $1.6B |
| 负债/权益比越低杠杆越低 | 1.63× | 0.77× |
8季度趋势，按日历期对齐
现金及短期投资AMAMPH
| Q1 26 | $180.4M | — | ||
| Q4 25 | $180.4M | $282.8M | ||
| Q3 25 | — | $276.2M | ||
| Q2 25 | — | $231.8M | ||
| Q1 25 | — | $236.9M | ||
| Q4 24 | — | $221.6M | ||
| Q3 24 | — | $250.5M | ||
| Q2 24 | — | $217.8M |
总债务AMAMPH
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $608.7M | ||
| Q3 25 | $3.0B | $608.6M | ||
| Q2 25 | $3.0B | $607.7M | ||
| Q1 25 | $3.1B | $603.9M | ||
| Q4 24 | $3.1B | $601.6M | ||
| Q3 24 | $3.2B | $596.4M | ||
| Q2 24 | $3.2B | $586.9M |
股东权益AMAMPH
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | $788.8M | ||
| Q3 25 | $2.1B | $776.7M | ||
| Q2 25 | $2.1B | $757.5M | ||
| Q1 25 | $2.1B | $751.3M | ||
| Q4 24 | $2.1B | $732.3M | ||
| Q3 24 | $2.1B | $727.7M | ||
| Q2 24 | $2.1B | $713.3M |
总资产AMAMPH
| Q1 26 | $5.9B | — | ||
| Q4 25 | $5.9B | $1.6B | ||
| Q3 25 | $5.7B | $1.7B | ||
| Q2 25 | $5.7B | $1.6B | ||
| Q1 25 | $5.8B | $1.6B | ||
| Q4 24 | $5.8B | $1.6B | ||
| Q3 24 | $5.8B | $1.5B | ||
| Q2 24 | $5.8B | $1.5B |
负债/权益比AMAMPH
| Q1 26 | 1.63× | — | ||
| Q4 25 | 1.63× | 0.77× | ||
| Q3 25 | 1.46× | 0.78× | ||
| Q2 25 | 1.45× | 0.80× | ||
| Q1 25 | 1.49× | 0.80× | ||
| Q4 24 | 1.47× | 0.82× | ||
| Q3 24 | 1.49× | 0.82× | ||
| Q2 24 | 1.50× | 0.82× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $198.9M | $32.9M |
| 自由现金流经营现金流 - 资本支出 | — | $24.6M |
| 自由现金流率自由现金流/营收 | — | 13.4% |
| 资本支出强度资本支出/营收 | 11.1% | 4.5% |
| 现金转化率经营现金流/净利润 | 1.65× | 1.35× |
| 过去12个月自由现金流最近4个季度 | — | $121.2M |
8季度趋势，按日历期对齐
经营现金流AMAMPH
| Q1 26 | $198.9M | — | ||
| Q4 25 | $255.5M | $32.9M | ||
| Q3 25 | $212.8M | $52.6M | ||
| Q2 25 | $265.2M | $35.6M | ||
| Q1 25 | $198.9M | $35.1M | ||
| Q4 24 | $232.7M | $29.0M | ||
| Q3 24 | $184.9M | $60.0M | ||
| Q2 24 | $215.8M | $69.1M |
自由现金流AMAMPH
| Q1 26 | — | — | ||
| Q4 25 | — | $24.6M | ||
| Q3 25 | — | $47.2M | ||
| Q2 25 | — | $25.0M | ||
| Q1 25 | — | $24.4M | ||
| Q4 24 | — | $16.6M | ||
| Q3 24 | $184.3M | $46.2M | ||
| Q2 24 | $147.2M | $63.1M |
自由现金流率AMAMPH
| Q1 26 | — | — | ||
| Q4 25 | — | 13.4% | ||
| Q3 25 | — | 24.6% | ||
| Q2 25 | — | 14.3% | ||
| Q1 25 | — | 14.3% | ||
| Q4 24 | — | 8.9% | ||
| Q3 24 | 68.3% | 24.1% | ||
| Q2 24 | 54.6% | 34.6% |
资本支出强度AMAMPH
| Q1 26 | 11.1% | — | ||
| Q4 25 | — | 4.5% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 6.3% | ||
| Q4 24 | 0.0% | 6.7% | ||
| Q3 24 | 0.2% | 7.2% | ||
| Q2 24 | 25.4% | 3.3% |
现金转化率AMAMPH
| Q1 26 | 1.65× | — | ||
| Q4 25 | 4.92× | 1.35× | ||
| Q3 25 | 1.84× | 3.03× | ||
| Q2 25 | 2.13× | 1.15× | ||
| Q1 25 | 1.65× | 1.39× | ||
| Q4 24 | 2.09× | 0.76× | ||
| Q3 24 | 1.85× | 1.48× | ||
| Q2 24 | 2.51× | 1.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AM
| Gathering and compression–Antero Resources | $238.0M | 82% |
| Other | $52.3M | 18% |
| Water handling–third party | $505.0K | 0% |
| Gathering and compression–third party | $295.0K | 0% |
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
